Summary

Overview
Global Graves Ophthalmopathy Treatment Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.
Graves ophthalmopathy is an autoimmune inflammatory disorder of the orbit and periorbital tissues that is characterized by upper eyelid retraction, lid lag, swelling, redness, conjunctivitis, and bulging eyes. The autoantibodies target the fibroblasts in the eye muscles, and those fibroblasts will differentiate into fat cells. Fat cells and muscles expand and become inflamed.
The disease can be treated by regulating the thyroid hormone levels. Corticosteroids are efficient in reducing orbital inflammation. The medication teprotumumab is also used to treat the condition.
Market Dynamics: Drivers & Restraints
Increasing prevalence of the disease
The increasing prevalence of the disease increases the demand for a variety of medications available and the increasing awareness among individuals about the disease increases the number of individuals undergoing treatment.
The increased prevalence is increasing the demand for precision medicine which suits the individual’s immune system without causing allergies or side effects to the individual. The disease is more common in women when compared to men. For instance, according to the Nature Journal in 2023, it is estimated that Graves ophthalmopathy incidence is 2.4 times more common in women than in men. Thus, the above factors are expected to drive market growth during the forecast period.
Restraint
Side effects associated with the medication
The side effects associated with the long-term intake of anti-inflammatory drugs specifically corticosteroids are associated with serious adverse effects such as osteoporosis, and thinning of the skin. The IV medication can cause side effects such as nausea, diarrhea, muscle spasms, and elevated blood sugar levels.
Segment Analysis
The global graves ophthalmopathy treatment market is segmented based on medication, route of administration, distribution channel, and region.
Corticosteroids segment accounted for 38.6% of the market share
Corticosteroids are considered the first-line therapy for the treatment of Graves' ophthalmopathy. It is a complicated autoimmune disease that can be prevented with the usage of corticosteroids. The efficiency of the corticosteroid medication against the disease is expected to hold the segment in the dominant position.
Corticosteroid Pulse Therapy for Graves' Ophthalmopathy reduces the relapse rate of Graves' hyperthyroidism. Glucocorticoid therapy is the mainstay of treatment especially for active moderate to severe patients, which needs evidence-based support.
The treatment of active moderate-severe Graves' ophthalmopathy (GO) is based on the administration of high-dose intravenous glucocorticoids (GCiv). Corticosteroids, alone or in combination with radiotherapy of the orbit, are widely used to treat severe Graves' ophthalmopathy. Thus, the above factors are holding the segment in the dominant position in the market share.
Geographical Analysis
North America is expected to hold a significant position in the global Graves ophthalmopathy treatment market share
North American region accounted for the largest market share. The increasing prevalence of the disease, the research carried out in introducing the medications, and the increased pharmaceutical production in the region is expected to drive the market growth in the region.
For instance, according to a report by the National Organization for Rare Disorders, Inc. (NORD) in 2022, it is estimated that the Graves ophthalmopathy occurrence is 16 per 100,000 women in the general population and 2.9 per 100,000 men in the general population. Thus, the increasing prevalence of the disease is expected to drive the market growth in the region.
COVID-19 Impact Analysis
The COVID-19 has impacted the Graves ophthalmopathy market moderately. The obstruction in the supply chain, the reduced approvals of the drugs, and the shift of the pharmaceutical companies towards the manufacturing of COVID-19 medicine has impacted the market negatively.
Market Segmentation
By Medication
• Corticosteroids
o Prednisolone
o Dehydrocortisone
o Glucocorticoids
• Insulin-like growth factor-1
o Teprotumumab
• Thionamides
• Radioiodine
By Route of Administration
• Oral
• Parenteral
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The leading companies with a significant market share include Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutics, Regeneron Pharmaceuticals, HanAll Biopharma, ValenzaBio, and Bausch & Lomb among others.
Why Purchase the Report?
• To visualize the global graves ophthalmopathy treatment market segmentation based on medication, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of graves ophthalmopathy treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global Graves ophthalmopathy treatment market report would provide approximately 55 tables, 56 figures, and 179 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Medication
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing prevalence of the disease
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Side effects associated with the medication
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Medication
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
7.1.2. Market Attractiveness Index, By Medication
7.2. Corticosteroids*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.2.1. Prednisolone
7.2.2.2. Dehydrocortisone
7.2.2.3. Glucocorticoids
7.3. Insulin-like growth factor-1
7.3.1. Teprotumumab
7.4. Thionamides
7.5. Radioiodine
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Parenteral
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Immunovant Sciences*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Novartis
12.3. Viridian Therapeutics
12.4. Sling Therapeutics
12.5. Regeneron Pharmaceuticals
12.6. HanAll Biopharma
12.7. ValenzaBio
12.8. Bausch & Lomb
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us